A multicenter clinical trial reports that intramuscular sotrovimab achieved viral load reductions comparable to intravenous infusion in outpatients with early mild-to-moderate COVID-19. The result strengthens the case for simpler administration routes that could expand practical access during periods of demand variability. The study directly compares intramuscular administration with standard IV dosing and reports matching clearance performance in early viral kinetics. The key operational implication is a potentially less resource-intensive delivery model without sacrificing early antiviral effect. While the dataset focuses on viral clearance rather than longer-term endpoints, it addresses a major logistical barrier for monoclonal antibody delivery in outpatient settings. For developers and health-system planners, the finding supports pathway decisions around formulation, administration training, and deployment readiness.